Monkeypox is a disease that continues to be under health surveillance in several countries, especially in Central and Eastern Africa due to its prevalence.
Although 38,671 cases of monkeypox have been reported worldwide so far this year, it is not considered a global epidemic. Nevertheless, the WHO continues to closely monitor the virus. This surveillance work includes the development of these lists of diagnostic tests considered essential by this organization.
Inclusion in this list acknowledges the quality, safety, and performance of our VIASURE Monkeypox Virus Real Time PCR Detection Kit, enabling its acquisition by international organizations and laboratories that are part of the WHO’s global surveillance network.
This product has been developed and marketed by Certest since 2022 through Viasure, its specialized Molecular Biology unit. It offers fast, specific, and reliable diagnostics—capable of distinguishing monkeypox from other similar diseases, facilitating rapid patient diagnosis and epidemiological control.
Moreover, it’s worth noting that the kit includes lyophilized reagents, allowing it to be stored at room temperature. This is a significant advantage, especially considering that countries with the highest incidence of this virus often lack optimal storage conditions.
